Location of Repository

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder

By P Sobocki, M Ekman, A Ovanfors, R Khandker and B Jönsson
Topics: Original Articles
Publisher: Blackwell Publishing Ltd
OAI identifier: oai:pubmedcentral.nih.gov:2327222
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2007). A ˚gren H et al. Health-related quality-of-life measured with EQ-5D in patients treated for depression in primary care. Value Health
    2. (2006). A ˚gren H et al. Model to assess the costeffectiveness of new treatments for depression.
    3. (2007). A ˚gren H et al. Resource-use and costs associated with patients treated for depression in primary care.
    4. (2006). A ˚gren H et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression.
    5. (2000). American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder (revision).
    6. (2001). Assessment of clinical guidelines for continuation treatment in major depression. Value Health
    7. (2005). Betalningsviljan fo ¨r ett kvalitetsjusterat levnadsa ˚r – en pilotstudie. Institutet fo ¨rH a ¨lsoekonomi. http://www.ihe.se/publiceringar/ihe_e-rapport_2005_1.htm (accessed
    8. British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.
    9. (2003). Clin Psychiatry
    10. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry
    11. (2001). Continuation and maintenance therapy in depression.
    12. (1998). Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics
    13. (2003). Cost of lost productive work time among US workers with depression. JAMA
    14. (1995). Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials
    15. (2008). Cost-effectiveness of maintenance treatment in depression ª
    16. (2000). Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder. Value Health
    17. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the
    18. (2003). General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2).
    19. (1999). Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess
    20. (2003). Health services need knowledge of how the public values health. La ¨kartidningen
    21. (2000). Multiple recurrences of major depressive disorder.
    22. (2003). Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy.
    23. (1997). Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confi-dence interval estimation. Health Econ
    24. (2008). Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000; 22: 153–62. Cost-effectiveness of maintenance treatment in depression 631 ª
    25. (1999). Recurrence after recovery from major depressive disorder during 15 years of observational follow-up.
    26. (2003). Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci
    27. (2006). Recurrence prevention: Efficacy of Two Years of Maintenance Treatment with Venxalafine XR in Patients with Recurrent Unipolar Major Depression.
    28. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet
    29. (2005). Remission from depression: a review of venlafaxine clinical and economic evidence. Pharmacoeconomics
    30. (2006). Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a metaanalysis of head-to-head trials. Curr Med Res Opin
    31. (2006). Statistical Year Book of Sweden.
    32. (1997). Suicide as an outcome for mental disorders. A meta-analysis.
    33. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res
    34. (2004). The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry
    35. The economic burden of depression in the United States: how did it change between
    36. (1999). The effect of episodes on recurrence in affective disorder: a case register study.
    37. (2004). The Swedish Council on Technology Assessment in Health Care (SBU). Behandling av depressionssjukdomar – En systematisk litteraturo ¨versikt (Treatment of depression).
    38. (1960). The value of medical spending in the United States,
    39. Treatment of Major Depression.
    40. (1998). US and UK health economics: two disciplines separated by a common language? Health Econ
    41. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health
    42. (2005). Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Mak

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.